Vertex Pharmaceuticals Incorporated (VRTX) Revenue by Segment
Vertex Pharmaceuticals revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), Vertex Pharmaceuticals's largest product or service was Cystic Fibrosis Products, with $3.21 billion or 96% of revenue, up 10.6% from a year earlier. Next: Casgevy (2%) and Journavx (1%).
By region, United States brought in 62%, Europe brought in 29% and Other Countries Outside of the United States and Europe brought in 9% of revenue in Q2 fiscal 2026.
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q1 fiscal 2017.
Vertex Pharmaceuticals Incorporated
Revenue breakdown
Fiscal quarters, from company filings
Vertex Pharmaceuticals revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Cystic Fibrosis Products | $3.2B | $2.9B | – | $2.9B | 96% |
| Casgevy | $76.4M | $42.9M | – | $30.4M | 2% |
| Journavx | $49.6M | $29.0M | – | $12.0M | 1% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Vertex Pharmaceuticals revenue by region, last 4 quarters
| Region | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| United States | $2.1B | $1.8B | $2.0B | $1.8B | 62% |
| Europe | $977.7M | $950.0M | $836.9M | $910.9M | 29% |
| Other Countries Outside of the United States and Europe | $299.8M | $261.0M | $263.2M | $205.6M | 9% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for Vertex Pharmaceuticals?
Cystic Fibrosis Products: $3.21 billion, or 96% of revenue, in Q2 fiscal 2026.
What are Vertex Pharmaceuticals's main products and services?
By revenue in Q2 fiscal 2026: Cystic Fibrosis Products (96%), Casgevy (2%) and Journavx (1%).
Where does Vertex Pharmaceuticals make its money?
By region in Q2 fiscal 2026: United States (62%), Europe (29%) and Other Countries Outside of the United States and Europe (9%).
